Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2019
|
| gptkbp:ATCCode |
N07XX14
|
| gptkbp:form |
injection
solution for injection |
| gptkbp:frequency |
once monthly
|
| gptkbp:genericName |
gptkb:givosiran
|
| https://www.w3.org/2000/01/rdf-schema#label |
GIVLAARI
|
| gptkbp:indication |
gptkb:acute_hepatic_porphyria
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Alnylam_Pharmaceuticals
|
| gptkbp:mechanismOfAction |
gptkb:RNA_interference
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
nausea
fatigue injection site reaction rash elevated liver enzymes |
| gptkbp:status |
FDA approved
|
| gptkbp:target |
aminolevulinate synthase 1 (ALAS1)
|
| gptkbp:bfsParent |
gptkb:NASDAQ:_ALNY
|
| gptkbp:bfsLayer |
7
|